Showing 2311-2320 of 4166 results for "".
- Navilas at AAO 2019: Laser is Back with Digital Guidance for Posterior Segment Treatmentshttps://modernod.com/news/navilas-at-aao-2019-laser-is-back-with-digital-guidance-for-posterior-segment-treatments/2476955/At this week’s AAO in San Francisco, OD-OS will be showcasing its Navilas 577s laser platform. The Navilas 577s is a retina laser with integrated eye tracking technology, a transparent workflow, and documentation which proves in clinics and teaching hospitals to be the next generation digital las
- First Clinical Program Initiated Using Nanoparticles to Treat Retinitis Pigmentosahttps://modernod.com/news/first-clinical-program-initiated-using-nanoparticles-to-treat-retinitis-pigmentosa/2476490/2Ctech announced the initiation of the first-known clinical program to demonstrate the effectiveness and safety of Quantum Dots (QDs) to achieve photovoltaic stimulation of the neural retina for preservation or enhancement of vision in patients with retinal degenerative diseases and, in particula
- FDA Wins Case Against Florida Stem Cell Clinic that Harmed three Women’s Visionhttps://modernod.com/news/fda-wins-case-against-florida-stem-cell-clinic-that-harmed-three-womens-vision/2476631/The FDA has won a federal judge’s backing for its efforts to crack down on the rapidly growing stem cell industry that promises all kinds of unproven treatments for serious diseases, according to an NBC News
- Johnson & Johnson Vision to Present New Data at AAO Demonstrating Benefits That New Innovations in Cataract Surgery Will Provide to Physicians and Patientshttps://modernod.com/news/johnson-johnson-vision-to-present-new-data-at-aao-demonstrating-benefits-that-new-innovations-in-cataract-surgery-will-provide-to-physicians-and-patients/2480412/Johnson & Johnson Vision will present a range of company-sponsored studies supporting new innovations in its cataract
- SightGlass Vision Reports on 2-Year Chinese Study for DOT Spectacle Lenses for Myopiahttps://modernod.com/news/sightglass-vision-reports-on-2-year-chinese-study-for-dot-spectacle-lenses-for-myopia/2486985/Key Takeaways SightGlass Vision’s DOT spectacle lenses reduced myopia progression by more than 1D on average after 2 years in Chinese children aged 6 to 10
- Tickets and Sponsorships Available for 2026 Prevent Blindness Person of Vision Award Gala Honoring Jim McGrannhttps://modernod.com/news/tickets-and-sponsorships-available-for-2026-prevent-blindness-person-of-vision-award-gala-honoring-jim-mcgrann/2485427/Prevent Blindness has announced that tickets and sponsorship opportunities remain available for the 2026 Prevent Blindness Person of Vision Award gala, which will honor Jim McGrann, CEO of Advancing Eyecare, for his decades of leadership and dedication to improving
- The Vision Council Urges Commerce Department to Exclude Optical Products from Potential Tariffshttps://modernod.com/news/the-vision-council-urges-commerce-department-to-exclude-optical-products-from-potential-tariffs/2484295/The Vision Council has submitted formal comments to the US Department of Commerce opposing potential new tariffs that could affect essential optical products and equipment. The comments respond to two ongoing Section 2
- Myra Vision Secures FDA Approval to Initiate US-Based IDE Study in Glaucomahttps://modernod.com/news/myra-vision-secures-fda-approval-to-initiate-us-based-ide-study-in-glaucoma/2482933/Myra Vision announced today that the FDA has issued a conditional approval letter for its investigational device exemption (IDE) application, allowing the company to initiate the ADAPT study. The prospective, nonr
- Arctic Vision Executes Collaboration Agreement with Santen for ARVN001 for the Treatment of Uveitic Macular Edemahttps://modernod.com/news/clearside-biomedical-partner-arctic-vision-executes-commercial-collaboration-agreement-with-santen-pharmaceutical-co-for-arvn001-suprachoroidal-space-injection-therapy-for-the-treatment-of-uveitic-macular-edema/2482529/Clearside Biomedical announced that its Asia-Pacific partner, Arctic Vision, has signed a new commercial collaboration agreement with Santen Pharmaceutical for ARVN001, branded in the United States as Xipere, for the treatment of uveitic macular edema
- Life After Death for the Human Eye: Vision Scientists Revive Light-Sensing Cells in Organ Donor Eyeshttps://modernod.com/news/life-after-death-for-the-human-eye-vision-scientists-revive-light-sensing-cells-in-organ-donor-eyes/2480858/Scientists have revived light-sensing neuron cells in organ donor eyes and restored communication between them as part of a series of discoveries that stand to transform brain and vision research, accor